AKT1 Antibody (C-term) Blocking Peptide

AKT1 Antibody (C-term) Blocking Peptide

€293.00
In stock
SKU
AC-BP7028b
Catalog Number: AC-BP7028b
Size: 500 µg
Datasheet

Request Information
Background:
The serine-threonine protein kinase encoded by the AKT1 gene is catalytically inactive in serum-starved primary and immortalized fibroblasts. AKT1 and the related AKT2 are activated by platelet-derived growth factor. The activation is rapid and specific, and it is abrogated by mutations in the pleckstrin homology domain of AKT1. It was shown that the activation occurs through phosphatidylinositol 3-kinase. In the developing nervous system AKT is a critical mediator of growth factor-induced neuronal survival. Survival factors can suppress apoptosis in a transcription-independent manner by activating the serine/threonine kinase AKT1, which then phosphorylates and inactivates components of the apoptotic machinery.

Other Names: RAC-alpha serine/threonine-protein kinase, Protein kinase B, PKB, Protein kinase B alpha, PKB alpha, Proto-oncogene c-Akt, RAC-PK-alpha, AKT1, PKB, RAC

Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP7028b was selected from the C-term region of human AKT1 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Type: Synthetic peptide

Primary Accession: P31749

Gene ID: 207

Gene Name: AKT1

Format: The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.

Bio References:
Liao, Y., et al., Int. J. Cancer 107(4):676-680 (2003).Powell, D.J., et al., Mol. Cell. Biol. 23(21):7794-7808 (2003).Debnath, J., et al., J. Cell Biol. 163(2):315-326 (2003).Li, G., et al., Oncogene 22(44):6891-6899 (2003).Liao, Y., et al., Mol. Cell. Biol. 23(19):6836-6848 (2003).
More Information
Is Featured? No
Write Your Own Review
You're reviewing:AKT1 Antibody (C-term) Blocking Peptide